WG1 - Accessible Data Network project

Convenor: Gary Francois, Manager Technologies Cancer Alliance Queensland

This working group aims to:

  • Streamline data extraction and AusCAT node set-up tools
  • Expansion and refinement of data extraction tools used with AusCAT, CAQ and CaVa and automated deployment of AusCAT learning tools.
  • Expansion of data items available across all 3 platforms.
  • Add further centres to the AusCAT platform in a streamlined manner.

Focus to date:

  • Gained understanding of participating team’s platforms – CAQ, CaVA & AusCAT
  • Performed analysis of data availability, data transformation and harmonisation from the three participating platforms
  • Commencement of documentation for the comparison of data availability between sites, including the ongoing sourcing of data to ensure consistent data availability, sources of data, extraction methods and pathways to obtain data
  • Learn and share techniques regarding data extraction between teams
  • Report outcomes of indicators within pathway of care and health service delivery framework
  • In Qld a local project will test the implementation of AusCAT node in the CAQ environment linking with the Princess Alexandria Hospital Radiation Oncology Service which will include the use of radiation therapy planning data from radiation therapy source system and linking to CAQ data from QOR

The focus for this collaboration and data learning between AusCAT, CAQ and CaVa platforms will be Lung cancer key performance indicators.

Possible indicators include:

  1. Patients receive pathological tissue diagnosis to enable definitive diagnosis and inform patients, carers and clinicians about the nature of the disease, likely prognosis and treatment choice.

  2. Patients receive confirmed clinical stage (cTNM) as part of the diagnosis to inform planning and subsequent treatment.

  3. Patients are offered radiation therapy where surgery is not feasible

  4. Patients receive appropriate end-of-life care, improving symptom control and quality of life while minimising treatment burden and side effects